A novel application of radiomimetic compounds as antibiotic drugs

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 10, 2015, Pages 1371-1379

  Andros, Christina C ^a   Dubay, Ryan A ^a   Mitchell, Kayleigh D ^a   Chen, Aaron ^a   Holmes, Dawn E ^a   Kennedy, Daniel R ^a  

^a WESTERN NEW ENGLAND UNIVERSITY   (United States)

Author keywords

antibiotics; bleomycin; calicheamicin; neocarzinostatin; radiomimetics

Indexed keywords

ANTIBIOTIC C 1027; BLEOMYCIN; CALICHEAMICIN; CHLORAMPHENICOL; PENICILLIN DERIVATIVE; TALLYSOMYCIN S 10B; TETRACYCLINE DERIVATIVE; ZINOSTATIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC ANTIBIOTIC; ENEDIYNE; GLYCOPEPTIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; CULTURE MEDIUM; DISK DIFFUSION; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA SICCA; NONHUMAN; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; COMPARATIVE STUDY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENEDIYNES; GLYCOPEPTIDES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS;

EID: 84941176798     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12432     Document Type: Article

References (47)

1. European Centre for Disease Prevention Control. The Bacterial Challenge, Time to React: A Call to Narrow the Gap between Multidrug-Resistant Bacteria in the EU and the Development of New Antibacterial Agents: ECDC; 2009.
2. Spellberg B, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-164.
3. White AR,. Discovery BWPoTUNRAD, Development. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011; 66: 1948-1953.
4. Petersson F, et al. Free flow acoustophoresis: microfluidic-based mode of particle and cell separation. Anal Chem 2007; 79: 5117-5123.
5. Ishida N, et al. Neocarzinostatin, an antitumor antibiotic of high molecular weight. Isolation, physiochemical properties and biological activities. J Antibiot 1965; 18: 68-76.
6. Ichikawa T, et al. Biological studies on bleomycin A. J Antibiot 1967; 20: 149-155.
7. Hu JL, et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot 1988; 41: 1575-1579.
8. Maiese WM, et al. Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J Antibiot 1989; 42: 558-563.
9. Xi Z, Goldberg IH,. DNA-damaging enediyne compounds. In:, Barton DHR, et al., eds. Comprehensive Natural Products Chemistry. Oxford, UK: Elsevier Science, 1999: 553-592.
10. Smith AL, Nicolaou KC,. The enediyne antibiotics. J Med Chem 1996; 39: 2103-2117.
11. Povirk LF,. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res 1996; 355: 71-89.
12. Chen J, Stubbe J,. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005; 5: 102-112.
13. Poddevin B, et al. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991; 42 (Suppl.): S67-S75.
14. Kennedy DR, Beerman TA,. The radiomimetic enediyne C-1027 induces unusual DNA damage responses to double-strand breaks. Biochemistry 2006; 45: 3747-3754.
15. Stratton CW,. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9: 10-16.
16. Dantes R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173: 1970-1978.
17. Wiegand I, et al. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-175.
18. Klevens RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771.
19. Clinical and Laboratory Standards Institute (CLSI). 2010. Performance standards for antimicrobial susceptibility testing; approved standard, 20th informational supplement M100-S20. CLSI, Wayne, PA.
20. Nomura T, et al. Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. Nihon Ketsueki Gakkai Zasshi 1990; 53: 98-104.
21. Weigert O, et al. Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets. Thromb Haemost 2008; 100: 705-707.
22. Pachioni Jde A, et al. Alkylphospholipids-a promising class of chemotherapeutic agents with a broad pharmacological spectrum. J Pharm Pharm Sci 2013; 16: 742-759.
23. In brief: miltefosine for amebic meningeoencephalitis available from CDC. Med Lett Drugs Ther 2013; 55: 88. http://secure.medicalletter.org/w1428d
24. Delcour AH,. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 2009; 1794: 808-816.
25. Sun J, et al. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun 2014; 453: 254-267.
26. Cassat JE, Skaar EP,. Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity. Semin Immunopathol 2012; 34: 215-235.
27. Liu W, Shen B,. Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globisporus are clustered with the cagA gene that encodes the C-1027 apoprotein. Antimicrob Agents Chemother 2000; 44: 382-392.
28. Davies JC, Bilton D,. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009; 54: 628-640.
29. Hancock RE, Speert DP,. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 2000; 3: 247-255.
30. Unemo M, et al. Challenges with gonorrhea in the era of multi-drug and extensively drug resistance-are we on the right track? Expert Rev Anti Infect Ther 2014; 12: 653-656.
31. Nicolaou KC, et al. Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 1993; 90: 5881-5888.
32. Sznaidman ML, Hecht SM,. Studies on the total synthesis of tallysomycin. Synthesis of the threonylbithiazole moiety containing a structurally unique glycosylcarbinolamide. Org Lett 2001; 3: 2811-2814.
33. Galm U, et al. In vivo manipulation of the bleomycin biosynthetic gene cluster in Streptomyces verticillus ATCC15003 revealing new insights into its biosynthetic pathway. J Biol Chem 2008; 283: 28236-28245.
34. Huang SX, et al. A designer bleomycin with significantly improved DNA cleavage activity. J Am Chem Soc 2012; 134: 13501-13509.
35. Kennedy DR, et al. Designer enediynes generate DNA breaks, interstrand cross-links, or both, with concomitant changes in the regulation of DNA damage responses. Proc Natl Acad Sci USA 2007; 104: 17632-17637.
36. Liu W, et al. Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 2002; 297: 1170-1173.
37. Liu W, et al. The neocarzinostatin biosynthetic gene cluster from Streptomyces carzinostaticus ATCC 15944 involving two iterative type I polyketide synthases. Chem Biol 2005; 12: 293-302.
38. Tao M, et al. The tallysomycin biosynthetic gene cluster from Streptoalloteichus hindustanus E465-94 ATCC 31158 unveiling new insights into the biosynthesis of the bleomycin family of antitumor antibiotics. Mol Biosyst 2007; 3: 60-74.
39. Beerman TA, et al. The radiomimetic enediyne 20'-deschloro-C-1027 induces inter-strand DNA crosslinks in hypoxic cells and overcomes cytotoxic radioresistance. DNA Repair (Amst) 2014; 21: 165-170.
40. Kennedy DR, et al. Single chemical modifications of the C-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks. Cancer Res 2007; 67: 773-781.
41. Horsman GP, et al. Polyketide synthase chemistry does not direct biosynthetic divergence between 9- and 10-membered enediynes. Proc Natl Acad Sci USA 2010; 107: 11331-11335.
42. Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013; 119: 2728-2736.
43. Yacoby I, Benhar I,. Targeted anti bacterial therapy. Infect Disord Drug Targets 2007; 7: 221-229.
44. Franzman MR, et al. Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int J Antimicrob Agents 2009; 33: 14-20.
45. Kaba HE, et al. Identification of whole pathogenic cells by monoclonal antibodies generated against a specific peptide from an immunogenic cell wall protein. J Microbiol Methods 2015; 108: 61-69.
46. Xu Y, et al. Bleomycin loaded magnetite nanoparticles functionalized by polyacrylic acid as a new antitumoral drug delivery system. BioMed Res Int 2013; 2013: 462589. http://www.hindawi.com/journals/bmri/2013/462589/
47. Lai HZ, et al. Potent antibacterial nanoparticles for pathogenic bacteria. ACS Appl Mater Interfaces 2015; 7: 2046-2054.